AI is deciding
whether your
brand exists
A researcher just asked ChatGPT which suppliers to shortlist for their next project. Your name may not have come up. Not because your product is weak. Because AI discoverability - and the emerging practices of generative engine optimisation (GEO) and answer engine optimisation (AEO) - operates by different rules. And most of the biotech, diagnostics and life science sector has not read them yet.
This hub collects Strivenn's primary research, content, frameworks, and a practical AI discoverability audit. Everything you need to move from invisible to cited.
The Wild West Rules of AI Discoverability
For the first time since Google's early days, the rules of discoverability are being rewritten in real time. Most life science marketers have not noticed yet. This is where the conversation starts.
What is query fan-out and why does it mean your number-one keyword ranking no longer guarantees AI visibility? Why does AI referral traffic convert at extraordinary rates despite driving less than 1% of total site visits? And why would you be making a serious strategic error by blocking the bots?
This is the long read that maps the full terrain: crawlers, citation mechanics, on-site structure, off-site signals, recency bias, and the five steps to take now.
0.77%
Current share of US desktop web activity from AI tools - tripled in 12 months from 0.24%
155%
Growth in LLM referral traffic over 8 months, versus 24% for traditional search
34.5%
Drop in position-one click-through rate when AI Overviews appear in search results
ELRIG Drug Discovery 2025: 68% AI Optimistic
Strivenn surveyed 107 exhibitors at ELRIG Drug Discovery 2025. The numbers should give every commercial leader pause. 68% are optimistic about AI's potential. Only 7% are power users. The rest are somewhere in between - with tools but no programmes, intentions but no infrastructure.
The survey reveals the original shape of what we now call the Programme Gap: 37% had AI tools without any structured adoption. 44% cited data quality as the primary barrier. And 62% had never asked an AI to recommend companies in their own category. Among those who had? Three quarters found themselves listed.
This is where the Unconsidered Set became visible as a pattern - not a hypothesis.
Disrupt Yourself, Before The Market Does
Three months after ELRIG. A different continent. 43 exhibitors at SLAS 2026 in Boston. The same survey. The same questions. And almost identical answers.
62% had never tested their AI visibility. 44% cited data quality as the primary barrier. But one number changed dramatically: power users nearly tripled - from 6.6% at ELRIG to 18.6% at SLAS. The top of the adoption curve is beginning to pull away from the rest.
The pattern is structural. The timeline is compressing. And the companies that disrupted themselves proactively are the ones showing up in AI recommendation lists.
The question is whether you get ahead of that curve or wait for it to pass you.
6.6%
AI power users at ELRIG DD 2025, October
18.6%
AI power users at SLAS 2026, January - nearly tripled in 3 months
62%
of exhibitors never tested their AI visibility
Separating Signal from Snake Oil in AI Search
Your agency just pitched you an Answer Engine Optimisation project. The deck was confident. Google's LLM Gemini called the aggressive version of this pitch spam. Before you redirect budget, you need to know what the evidence actually shows.
This is the strategic framing piece for the series. It cuts through agency hype using independent data and Google's own statements, calibrates the conversion claims you have probably been shown, and introduces the three frameworks that underpin everything else.
The underlying shift is real. The question is how real, how fast, and where it creates genuine commercial risk. This article gives you the tools to answer that for your own organisation.
The Unconsidered Set
The state of being absent from AI-generated consideration before you know you are absent. You do not lose the deal. You are never in the running. Applies to every biotech, diagnostics and life science tools brand operating without an AI discoverability programme.
The Programme Gap
Tool access without structured adoption produces near-zero commercial return. The pattern behind the AI maturity gap: 44% of commercial teams have AI tools and no programme to guide their use. Access is not adoption. Adoption is not advantage.
Citation Compression
AI visibility is narrowing to a handful of dominant brands per category. In repeated ChatGPT tests on B2B software prompts, around five brands appeared in 80% or more of answers. Unlike traditional search, which offered ten first-page positions, an AI recommendation list is far shorter. In B2B marketing terms, this is winner-takes-most - and it is already operating.
How AI Decides Who Gets Cited
You have spent years building domain authority. You rank on page one for your most important keywords. But when a researcher asks ChatGPT which suppliers to shortlist, you may not appear. Not because your content is poor. Because AI citation is not an extension of search ranking.
This article breaks down the mechanics: why brand recognition beats backlinks, what entity consistency actually means in practice, how content structure determines extractability, and why platform presence multiplies your citation probability.
Specific, actionable, evidence-backed. For the team responsible for making it happen.
41%
Increase in visibility in AI-generated answers when content adds quotations from credible sources
31%
Increase in visibility in AI-generated answers when content adds specific statistics
2.8X
More likely to appear in ChatGPT responses when a brand is mentioned on four or more platforms
Your Scientific Credibility Is an AI Search Weapon
In health and science domains, AI models do not behave like consumer search. Reddit and LinkedIn, two of the platforms most brand managers optimise for, barely register in AI citation analysis for health queries. NIH content appears in approximately 39% of Google AI Overview citations for health queries. ScienceDirect: 11.5%.
The platforms your scientists have been contributing to for years are the ones AI models prefer. Most life science marketing teams are not connecting these dots.
This article makes the case that your peer-reviewed publications, named expert authorship, and ungated scientific claims are structural AI citation magnets. The window to exploit that advantage is narrowing as Citation Compression sets in.
39%
of Google AI Overview citations for health queries go to NIH content. Social platforms barely register.
94%
of B2B buyers now use LLMs during the buying process - peaking mid-journey during comparison and RFP drafting
11.5%
of Google AI Overview citations for health queries go to ScienceDirect, home of peer-reviewed literature
The AI Discoverability Audit for Life Science Brands
Six phases. No specialist agency required. This is the operational guide that turns everything above into a specific action list - prioritised by impact and designed for your existing team.
-
Phase 1: Entity audit across six platforms.
-
Phase 2: Content accessibility and gated content strategy.
-
Phase 3: Technical configuration and bot access.
-
Phase 4: Content structure scoring for ten high-value pages.
-
Phase 5: Citation monitoring across five AI platforms.
-
Phase 6: Freshness cadence that keeps you retrievable.
The most important output is not the score. It is the habit of measurement. The companies with the clearest picture of where they stand will respond faster to every shift that follows.
The audit tells you where you stand. Strivenn's AI-powered inbound marketing systems help you close the gap. We combine entity strategy, structured content programmes, citation monitoring, and HubSpot implementation to build the infrastructure that earns life science, biotech and diagnostics brands a place in AI-generated consideration - consistently, not occasionally.
This is not agency retainer work. It is a structured AI maturity programme with measurable milestones and a clear commercial logic.
Exactly what the Programme Gap demands.
-
A structured AI discoverability programme with measurable milestones - not a one-off audit
-
Entity consistency audit across your website, LinkedIn, Crunchbase, and Wikidata
-
Content restructuring for AI extraction - self-contained, schema-marked, attributed
-
Named expert profiling to make your scientists AI-citable, not just credible
-
Monthly citation monitoring across ChatGPT, Perplexity, Google AI Mode, Copilot, and Claude
-
HubSpot implementation connecting AI visibility to inbound pipeline
Frequently asked questions about AI discoverability
What is AI discoverability for life science brands?
AI discoverability is the likelihood that ChatGPT, Perplexity, Google AI Mode, Copilot or Claude names your brand when a researcher asks which suppliers to consider. It covers the emerging practices of generative engine optimisation (GEO) and answer engine optimisation (AEO). For biotech, diagnostics and life science tools companies, it decides whether you reach the shortlist before any sales conversation starts.
How is AI discoverability different from SEO?
Search ranking and AI citation reward different signals. A page-one ranking earns you one link among ten. An AI answer names a handful of brands, and the models weight brand recognition, entity consistency across platforms, extractable content structure and recency. Strong SEO helps. It leaves gaps that only a deliberate AI discoverability programme closes.
What is the Unconsidered Set?
The Unconsidered Set is Strivenn's term for brands that are absent from AI-generated consideration without knowing it. The buyer never sees you, so there is no lost deal to report and no signal in your pipeline data. The pattern surfaced in Strivenn's ELRIG Drug Discovery 2025 exhibitor survey, where 62% of respondents had never asked an AI to recommend companies in their own category.
What is Citation Compression?
Citation Compression describes AI visibility narrowing to a handful of dominant brands in each category. In repeated ChatGPT tests on B2B software prompts, around five brands appeared in 80% or more of answers. A traditional results page offered ten first-page positions. An AI recommendation list is far shorter, so the brands already cited gain ground with every answer. For life science marketers, the window to claim a place is closing as each category consolidates.
Should life science companies block AI crawlers?
For most commercial content, no. Blocking crawlers such as GPTBot, ClaudeBot or PerplexityBot removes your pages from the sources AI models retrieve and cite, and hands your share of the answer to competitors. Keep genuinely confidential material gated. Keep product, application and scientific content open to the bots.
Why does scientific content help life science brands get cited by AI?
In health and science queries, AI models favour authoritative scientific sources. Surfer's AI citation research puts NIH content at roughly 39% of health citations and ScienceDirect at around 11.5%. Peer-reviewed publications, named expert authors and ungated scientific claims give your brand the signals these models already trust.
How do you audit your brand's AI discoverability?
Strivenn's AI Discoverability Audit runs in six phases: an entity audit across six platforms, content accessibility and gated content strategy, technical configuration and bot access, content structure scoring for ten high-value pages, citation monitoring across five AI platforms, and a freshness cadence that keeps you retrievable. Your existing team can run it without a specialist agency.
How quickly is AI changing B2B buying in life science?
Quickly. 6sense reports that 94% of B2B buyers now use LLMs during the buying process. Among the life science exhibitors Strivenn surveyed, AI power users rose from 6.6% at ELRIG Drug Discovery 2025 to 18.6% at SLAS 2026, three months later.